The effect of carvacrol on inflammatory mediators and respiratory symptoms in veterans exposed to sulfur mustard, a randomized, placebo-controlled trial

• Published in: Respiratory medicine 2019-04, Vol.150, p.21-29
• Main Authors: Khazdair, Mohammad Reza, Boskabady, Mohammad Hossein
• Format: Article
• Language: English
• Subjects: Airway management; Asthma; Carvacrol; Chemokine; Chemokine CCL2 - blood; Chemokines; Chemokines - blood; Chemokines - drug effects; Chronic obstructive pulmonary disease; Clinical trials; Cough; Cough - diagnosis; Cough - physiopathology; Cymenes - adverse effects; Cymenes - therapeutic use; Cytokines; Cytokines - blood; Cytokines - drug effects; Epidermal growth factor; Epidermal Growth Factor - blood; Evidence-based medicine; Exposure; Forced Expiratory Volume - drug effects; Growth factors; Humans; Inflammation; Inflammation Mediators - blood; Inhalation Exposure - adverse effects; Laboratories; Medical research; Middle Aged; Monocyte chemoattractant protein 1; Monocytes; Mustard gas; Mustard Gas - adverse effects; Night; Patients; Placebos - administration & dosage; Proteins; Respiratory Function Tests - methods; Respiratory Sounds - drug effects; Respiratory symptoms; Respiratory Tract Diseases - drug therapy; Respiratory Tract Diseases - metabolism; Respiratory Tract Diseases - physiopathology; Serum levels; Signs and symptoms; Sleep; Sulfur; Sulfur mustard; Terpenes - adverse effects; Terpenes - therapeutic use; Tumor Necrosis Factor-alpha - blood; Tumor necrosis factor-α; Values; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - blood; Veterans - statistics & numerical data
• ISSN: 0954-6111; 1532-3064
• DOI: 10.1016/j.rmed.2019.01.020

The aim of this study was to evaluate the effect of carvacrol on serum level of inflammatory mediators and respiratory symptoms in the veterans exposed to sulfur mustard (SM). Twenty-one patients who were exposed to SM more than two decades' ago were divided to placebo and carvacrol (1.2 mg/kg/day) treated groups. Serum levels of Tumor Necrosis Factor-α (TNF-α), Monocyte chemotactic protein-1 (MCP-1), Vascular endothelial growth factor (VEGF), Epidermal growth factor (EGF), forced expiratory volume-one second (FEV1) and respiratory symptoms including; Chest wheeze (CW), night wheeze (NW), night cough (NC) and cough and wheeze during exercise (ECW) were assessed at the baseline (step 0), one and two months after starting treatment (step I and II, respectively). FEV1 value was significantly increased in carvacrol treated group in step II compared to step 0 (p